To further validate the association between SETD2 mutation and MSI status, we also examined the MSI MANTIS10 scores in patients with SETD2 mutant cancer (0.32, 0.30–0.34) and patients with SETD2 nonmutant cancer (0.31, 0.29–0.33; P < 0.0001). This evidence concerns the gene SETD2 and cancer.